One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Access to COVID-19 vaccines: looking beyond COVAX
The Lancet
doi : 10.1016/S0140-6736(21)00617-6
EDITORIAL| VOLUME 397, ISSUE 10278, P941, MARCH 13, 2021
Semaglutide and effective weight control
Roberto Latini,Lidia Staszewsky
doi : 10.1016/S0140-6736(21)00377-9
COMMENT| VOLUME 397, ISSUE 10278, P942-943, MARCH 13, 2021
The vulnerable plaque detected: time to consider treatment
Ron Waksman,Rebecca Torguson
doi : 10.1016/S0140-6736(21)00504-3
COMMENT| VOLUME 397, ISSUE 10278, P943-945, MARCH 13, 2021
Addressing the global burden of hearing loss
Blake S Wilson,Debara L Tucci
doi : 10.1016/S0140-6736(21)00522-5
COMMENT| VOLUME 397, ISSUE 10278, P945-947, MARCH 13, 2021
Priorities for the COVID-19 pandemic at the start of 2021: statement of the Lancet COVID-19 Commission
Commissioners of the Lancet COVID-19 Commission,Task Force Chairs and members of the Lancet COVID-19 Commission,Commission Secretariat and Staff of the Lancet COVID-19 Commission
doi : 10.1016/S0140-6736(21)00388-3
COMMENT| VOLUME 397, ISSUE 10278, P947-950, MARCH 13, 2021
The changing face of medical professionalism and the impact of COVID-19
Andrew F Goddard,Mumtaz Patel
doi : 10.1016/S0140-6736(21)00436-0
COMMENT| VOLUME 397, ISSUE 10278, P950-952, MARCH 13, 2021
SARS-CoV-2 variants and ending the COVID-19 pandemic
Arnaud Fontanet,Brigitte Autran,Bruno Lina,Marie Paule Kieny,Salim S Abdool Karim,Devi Sridhar
doi : 10.1016/S0140-6736(21)00370-6
COMMENT| VOLUME 397, ISSUE 10278, P952-954, MARCH 13, 2021
Health in Syria: a decade of conflict
Sharmila Devi
doi : 10.1016/S0140-6736(21)00618-8
WORLD REPORT| VOLUME 397, ISSUE 10278, P955-956, MARCH 13, 2021
Australian Commission calls for overhaul of aged care
Sophie Cousins
doi : 10.1016/S0140-6736(21)00619-X
WORLD REPORT| VOLUME 397, ISSUE 10278, P957, MARCH 13, 2021
Countries split from EU on COVID-19 vaccines
Ed Holt
doi : 10.1016/S0140-6736(21)00620-6
WORLD REPORT| VOLUME 397, ISSUE 10278, P958, MARCH 13, 2021
A shared COVID-19 testimony
Rageshri Dhairyawan
doi : 10.1016/S0140-6736(21)00564-X
PERSPECTIVES|BOOK| VOLUME 397, ISSUE 10278, P959-960, MARCH 13, 2021
Yashica Robinson: championing reproductive health in Alabama
Richard Lane
doi : 10.1016/S0140-6736(21)00565-1
PERSPECTIVES|PROFILE| VOLUME 397, ISSUE 10278, P961, MARCH 13, 2021
John Keats, medicine, and poetry
Nicholas Roe
doi : 10.1016/S0140-6736(21)00450-5
PERSPECTIVES|THE ART OF MEDICINE| VOLUME 397, ISSUE 10278, P962-963, MARCH 13, 2021
Bernard Lown
Adam Marcus
doi : 10.1016/S0140-6736(21)00567-5
OBITUARY| VOLUME 397, ISSUE 10278, P964, MARCH 13, 2021
The USA's response to the 2014 Ebola outbreak could have informed its COVID-19 response
Syra Madad,Craig Spencer
doi : 10.1016/S0140-6736(21)00433-5
CORRESPONDENCE| VOLUME 397, ISSUE 10278, P965-966, MARCH 13, 2021
Sex-disaggregated data in COVID-19 vaccine trials
Lavanya Vijayasingham,Evelyne Bischof,Jeannette Wolfeon behalf of the Gender and COVID-19 Research Agenda-setting Initiative
doi : 10.1016/S0140-6736(21)00384-6
CORRESPONDENCE| VOLUME 397, ISSUE 10278, P966-967, MARCH 13, 2021
Clinician engineers—the time is now
Neel Sharma
doi : 10.1016/S0140-6736(21)00444-X
CORRESPONDENCE| VOLUME 397, ISSUE 10278, P967, MARCH 13, 2021
Long-haul COVID: heed the lessons from other infection-triggered illnesses
John N Aucott,Alison W Rebman
doi : 10.1016/S0140-6736(21)00446-3
CORRESPONDENCE| VOLUME 397, ISSUE 10278, P967-968, MARCH 13, 2021
Accountability framework to decolonise global health
Bolajoko O Olusanya
doi : 10.1016/S0140-6736(21)00378-0
CORRESPONDENCE| VOLUME 397, ISSUE 10278, P968, MARCH 13, 2021
Transformational learning to decolonise global health
Amali U Lokugamage,Sarah H M Wong,Nathan M A Robinson,Sithira D C Pathberiya
doi : 10.1016/S0140-6736(21)00371-8
CORRESPONDENCE| VOLUME 397, ISSUE 10278, P968-969, MARCH 13, 2021
Deepening community-aligned science in response to wavering trust in science
Michio Murakami,Masaharu Tsubokura
doi : 10.1016/S0140-6736(21)00358-5
CORRESPONDENCE| VOLUME 397, ISSUE 10278, P969-970, MARCH 13, 2021
Haiti's kidney transplantation unit
Jacques Maurice Jeudy,Gaetano Ciancio
doi : 10.1016/S0140-6736(21)00353-6
CORRESPONDENCE| VOLUME 397, ISSUE 10278, P970, MARCH 13, 2021
Department of Error
doi : 10.1016/S0140-6736(21)00563-8
DEPARTMENT OF ERROR| VOLUME 397, ISSUE 10278, P970, MARCH 13, 2021
Department of Error
doi : 10.1016/S0140-6736(21)00451-7
DEPARTMENT OF ERROR| VOLUME 397, ISSUE 10278, P970, MARCH 13, 2021
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
Melanie Davies,Louise F?rch,Ole K Jeppesen,Arash Pakseresht,Sue D Pedersen,Leigh Perreault,Julio Rosenstock,Iichiro Shimomura,Adie Viljoen,Thomas A Wadden,Ildiko Lingvayfor the STEP 2 Study Group
doi : 10.1016/S0140-6736(21)00213-0
ARTICLES| VOLUME 397, ISSUE 10278, P971-984, MARCH 13, 2021
This trial assessed the efficacy and safety of the GLP-1 analogue once a week subcutaneous semaglutide 2·4 mg versus semaglutide 1·0 mg (the dose approved for diabetes treatment) and placebo for weight management in adults with overweight or obesity, and type 2 diabetes.
Identification of vulnerable plaques and patients by intracoronary near-infrared spectroscopy and ultrasound (PROSPECT II): a prospective natural history study
David Erlinge,Akiko Maehara,Ori Ben-Yehuda,Hans Erik B?tker,Michael Maeng,Lars Kj?ller-Hansen,Thomas Engstr?m,Mitsuaki Matsumura,Aaron Crowley,Ovidiu Dressler,Gary S Mintz,Ole Fr?bert,Jonas Persson,Rune Wiseth,Alf Inge Larsen,Lisette Okkels Jensen,Jan Erik Nordrehaug,?yvind Bleie,Elmir Omerovic,Claes Held,Stefan K James,Ziad A Ali,James E Muller,Gregg W Stonefor the PROSPECT II Investigators
doi : 10.1016/S0140-6736(21)00249-X
ARTICLES| VOLUME 397, ISSUE 10278, P985-995, MARCH 13, 2021
Near-infrared spectroscopy (NIRS) and intravascular ultrasound are promising imaging modalities to identify non-obstructive plaques likely to cause coronary-related events. We aimed to assess whether combined NIRS and intravascular ultrasound can identify high-risk plaques and patients that are at risk for future major adverse cardiac events (MACEs).
Hearing loss prevalence and years lived with disability, 1990–2019: findings from the Global Burden of Disease Study 2019
GBD 2019 Hearing Loss Collaborators
doi : 10.1016/S0140-6736(21)00516-X
ARTICLES| VOLUME 397, ISSUE 10278, P996-1009, MARCH 13, 2021
Hearing loss affects access to spoken language, which can affect cognition and development, and can negatively affect social wellbeing. We present updated estimates from the Global Burden of Disease (GBD) study on the prevalence of hearing loss in 2019, as well as the condition's associated disability.
Mediastinal melioidosis masquerading as malignancy of the lung
Sze Shyang Kho,Yoke Fun Ho,Swee Kim Chan,Siew Teck Tie
doi : 10.1016/S0140-6736(21)00200-2
CLINICAL PICTURE| VOLUME 397, ISSUE 10278, E8, MARCH 13, 2021
Enhancing anti-tumour efficacy with immunotherapy combinations
Funda Meric-Bernstam,James Larkin,Josep Tabernero,Chiara Bonini
doi : 10.1016/S0140-6736(20)32598-8
REVIEW| VOLUME 397, ISSUE 10278, P1010-1022, MARCH 13, 2021
Several tumour types are responsive to immunotherapy, as shown by regulatory approvals for immune checkpoint inhibitors. However, many patients either do not respond or do not have durable clinical benefit. Thus, there is great interest in developing predictors of response to immunotherapy and rational combination therapies that can enhance efficacy by overcoming primary and acquired resistance. In this Review, we provide an assessment of immunotherapy response biomarkers that can identify patients who will benefit from monotherapy rather than from combinations. We review the rationale for combination therapy and different strategies, including combinations with chemotherapy, targeted therapy, radiation therapy, intratumoural therapies, other immunomodulators, and adaptive cell therapy, including chimeric antigen T-cell receptors and other novel T-cell receptor-based therapies. There are many combination partners in development; therefore, a programmatic approach is needed to develop a framework for biomarker-driven combination therapy selection.
Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment
Olivier J Wouters,Kenneth C Shadlen,Maximilian Salcher-Konrad,Andrew J Pollard,Heidi J Larson,Yot Teerawattananon,Mark Jit
doi : 10.1016/S0140-6736(21)00306-8
HEALTH POLICY| VOLUME 397, ISSUE 10278, P1023-1034, MARCH 13, 2021
The COVID-19 pandemic is unlikely to end until there is global roll-out of vaccines that protect against severe disease and preferably drive herd immunity. Regulators in numerous countries have authorised or approved COVID-19 vaccines for human use, with more expected to be licensed in 2021. Yet having licensed vaccines is not enough to achieve global control of COVID-19: they also need to be produced at scale, priced affordably, allocated globally so that they are available where needed, and widely deployed in local communities. In this Health Policy paper, we review potential challenges to success in each of these dimensions and discuss policy implications. To guide our review, we developed a dashboard to highlight key characteristics of 26 leading vaccine candidates, including efficacy levels, dosing regimens, storage requirements, prices, production capacities in 2021, and stocks reserved for low-income and middle-income countries. We use a traffic-light system to signal the potential contributions of each candidate to achieving global vaccine immunity, highlighting important trade-offs that policy makers need to consider when developing and implementing vaccination programmes. Although specific datapoints are subject to change as the pandemic response progresses, the dashboard will continue to provide a useful lens through which to analyse the key issues affecting the use of COVID-19 vaccines. We also present original data from a 32-country survey (n=26?758) on potential acceptance of COVID-19 vaccines, conducted from October to December, 2020. Vaccine acceptance was highest in Vietnam (98%), India (91%), China (91%), Denmark (87%), and South Korea (87%), and lowest in Serbia (38%), Croatia (41%), France (44%), Lebanon (44%), and Paraguay (51%).
